Literature DB >> 2806357

The effect of three dose levels of ICS 205-930 (a selective 5HT-3 antagonist) on cisplatin-induced nausea and vomiting.

H Seinen1, B A Zonnenberg, P Tjia, J P Neijt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2806357     DOI： 10.1016/0277-5379(89)90081-3

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  5 in total

Review 1.  5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis.

Authors:  M S Aapro
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 2.  Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 3.  Tropisetron. A review of the clinical experience.

Authors:  K M de Bruijn
Journal:  Drugs       Date:  1992       Impact factor: 9.546

4.  Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment.

Authors:  H Bleiberg; S Van Belle; R Paridaens; G De Wasch; L Y Dirix; M Tjean
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 5.  Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic.

Authors:  C R Lee; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.